Enanta Pharmaceuticals Inc (ENTA) — Cash Flow-to-Debt Ratio
Enanta Pharmaceuticals Inc (ENTA) has a Cash Flow-to-Debt Ratio of -0.04x as of March 2026, meaning its operating cash flow of $-7.16 Million could theoretically repay 0% of its total liabilities ($198.12 Million) in one year. Explore Enanta Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enanta Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Enanta Pharmaceuticals Inc across 15 annual periods. Also explore Enanta Pharmaceuticals Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Enanta Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Enanta Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Enanta Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.09x | $-19.27 Million | $216.01 Million | ▲ +71.9% |
| 2024 | -0.32x | $-78.76 Million | $247.84 Million | ▲ +24.4% |
| 2023 | -0.42x | $-103.15 Million | $245.54 Million | ▲ +70.6% |
| 2022 | -1.43x | $-84.78 Million | $59.26 Million | ▲ +15.3% |
| 2021 | -1.69x | $-70.00 Million | $41.43 Million | ▼ -939.2% |
| 2020 | 0.20x | $7.09 Million | $35.21 Million | ▼ -92.3% |
| 2019 | 2.61x | $71.42 Million | $27.34 Million | ▲ +83.7% |
| 2018 | 1.42x | $29.22 Million | $20.55 Million | ▼ -32.6% |
| 2017 | 2.11x | $52.65 Million | $24.96 Million | ▼ -33.2% |
| 2016 | 3.16x | $35.81 Million | $11.34 Million | ▼ -59.4% |
| 2015 | 7.78x | $76.67 Million | $9.86 Million | ▲ +160.6% |
| 2014 | 2.98x | $20.18 Million | $6.76 Million | ▲ +82.2% |
| 2013 | 1.64x | $10.65 Million | $6.50 Million | ▼ -40.4% |
| 2012 | 2.75x | $22.62 Million | $8.23 Million | ▲ +1708.2% |
| 2011 | 0.15x | $24.02 Million | $158.06 Million | — |